title: Mechanisms of Drug-Induced Interstitial Nephritis.
abstract: Drug-induced acute interstitial nephritis (DI-AIN) is a drug hypersensitivity reaction (DHR) that manifests 7 to 10 days after exposure to the culprit drug. DHRs account for fewer than 15% of reported adverse drug reactions. The kidneys are susceptible to DHR because: (1) the high renal blood flow whereby antigens are filtered, secreted, or concentrated, and (2) it is a major site of excretion for drugs and drug metabolites. More than 250 different drugs from various classes have been incriminated as causative agents of DI-AIN, the third most common cause of acute kidney injury in the hospital. DI-AIN must be differentiated from drug-induced nephrotoxic acute tubular necrosis because of their differing pathophysiology and treatment. DI-AIN begins with antigen processing and presentation to local dendritic cells. The dendritic cells activate T cells, and the subsequent effector phase of the immune response is mediated by various cytokines. Incriminated antigenic mechanisms include response to a conjugation product of the drug or its metabolite with a host protein (eg, beta-lactam or sulfonamide antibiotic) or the direct binding of the drug to a particular host allele to elicit a hypersensitivity response (eg, certain anti-epileptic drugs). If the offending drug is not identified and discontinued in a timely manner, irreversible fibrosis and chronic kidney disease will occur. The core structure of each drug or its metabolite is an antigenic determinant, and the host interaction is termed the structure-activity relationship. Differing structure-activity relationships accounts for effect, hypersensitivity, and cross-reactivity among and between classes. The essence of management of DI-AIN lies with the four sequential steps: anticipation, diagnosis, treatment, and prevention. Corticosteroids are used in the treatment of DI-AIN because of their potent anti-inflammatory effects on T cells and eosinophils. Anticipation and prevention require notifying the patient that DI-AIN is an idiosyncratic, hypersensitivity reaction that recurs on re-exposure, and the drug should be avoided.
authors.affiliation: Division of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX. Electronic address: rajeevr@bcm.edu.
authors.forename: Rajeev
authors.initials: R
authors.lastname: Raghavan
authors.affiliation: Division of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX.
authors.forename: Saed
authors.initials: S
authors.lastname: Shawar
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000150:complications* / Q000628:therapy; D000939:Epitopes; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000150:complications* / Q000628:therapy; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000276:immunology* / Q000628:therapy; D054328:Proton Pump Inhibitors / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D047090:beta-Lactams / Q000009:adverse effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000939:Epitopes; D054328:Proton Pump Inhibitors; D013449:Sulfonamides; D047090:beta-Lactams
keywords: Acute Kidney Injury; Drug Hypersensitivity Reaction; Drug-Induced; Interstitial Nephritis